Background: Cytomegalovirus (CMV) viremia after CD34 + -selected hematopoietic stem cell transplant (HCT) often requires prolonged antiviral therapy. We report rates and outcomes of resistant CMV in a contemporary cohort of CD34 + -selected HCT recipients managed preemptively.
| INTRODUC TI ON
CMV resistance after conventional hematopoietic stem cell transplant (HCT) is relatively uncommon, ranging from 1-5%. 1 Higher rates (6%-10%) have been reported after haploidentical HCT or in pediatric recipients of mismatched allografts. [1] [2] [3] Prolonged, subtherapeutic levels of antivirals and persistent CMV replication have been associated with emergence of CMV resistance. [4] [5] [6] Current treatment options for resistant CMV are limited and carry substantial toxicities. [7] [8] [9] Furthermore, CMV resistance has been associated with increased morbidity and mortality. [10] [11] [12] [13] Approximately 70% of CMV-seropositive recipients (R+) of CD34 + -selected allografts develop CMV viremia with a median onset of 28 days from HCT. Prolonged antiviral therapy is often required for viral suppression until immune reconstitution. 14 Rates of CMV resistance are not well defined in this population. In this retrospective study, we examined 1) the frequency and types of CMV resistance mutations; and 2) outcomes of resistant CMV after CD34 + -selected HCT.
| ME THODS

| Patients
A retrospective review was performed on 220 CMV R+ patients who underwent first CD34 + -selected HCT at Memorial Sloan Kettering Cancer Center (MSKCC) between June 2010 and December 2014. Patients were followed until death, second HCT, or 1 year from HCT, whichever occurred first. Clinical, laboratory, and pharmacy data were extracted from medical records and hospital databases. The study was reviewed and approved by the MSKCC Institutional Review Board, and was granted a waiver of authorization (WA0020-15).
| Transplant procedures
Graft manipulation and conditioning regimens have been previous described. 14 Ex vivo T-cell depletion was performed by the CliniMACS ® CD34 + Reagent System (Miltenyi, Biotec, Gladbach, Germany). Patients received conditioning with one of the following preparative regimens: busulfan/melphalan/fludarabine, total body irradiation/thio-TEPA/cyclophosphamide, or clofarabine/thio-TEPA/melphalan. Ninety percent were myeloablative. 15 All patients received antithymocyte globulin as part of the conditioning. 
TA B L E 1 Baseline characteristics of the cohort
| Supportive care
Supportive care was provided per the MSKCC standards of care.
14 All patients received standard antiviral prophylaxis with acyclovir for the first year from HCT. CMV R+ was routinely monitored by quantitative PCR in whole blood or plasma twice weekly starting on day +14 until discharge, at least weekly through day +100; at least once every 2 weeks through day +180 and at least monthly up to 1 year from HCT. Preemptive CMV treatment was initiated for a CMV viral load (VL) ≥1000 copies/mL in whole blood, VL ≥300 IU/mL in plasma samples, or increasing CMV VL trend in consecutive measurements. Standard induction treatment doses were administered until CMV VL was undetectable or detected at stable low level in several consecutive measurements followed by maintenance doses through weeks +12 from HCT or longer at clinician discretion. Valganciclovir (GCV) was 
| Laboratory methods
Since March 18, 2013, the Roche Amplicor PCR was used for routine CMV monitoring in plasma. The lower limit of detection was 81 IU/ mL and the linear range of quantitation 137-9 100 000 IU/mL. Prior to March 18, 2013, a home brewed assay was used for CMV monitoring in whole blood. The range of quantitation was 500-1 000 000 copies/mL. 16 CMV genotypic resistance testing was performed by
Viracor Eurofins (Lee's Summit, MO). Results were reported as location and type of amino-acid substitution of point mutations in CMV UL97 and UL54 genes and resistance to antivirals.
| Definitions
CMV viremia was defined as ≥1 positive PCR value above the lower limit of quantitation of the CMV assay used for monitoring. Persistent CMV viremia was defined as CMV VL ≥1000 IU/mL after 3 weeks of induction dose CMV antivirals. Maximum CMV VL was defined as the highest CMV VL detected by CMV PCR prior to day +180 from HCT or resistance testing, whichever occurred first. Resistant CMV was defined as the presence of resistance mutation through day +365. Early 
| Statistical analysis
Categorical and continuous variables were compared using Chisquare/Fisher's exact test and Mann-U-Whitney test, respectively.
All statistical analyses were completed using SAS 9.4 (SAS Inc., Cary, NC). All tests were two-tailed and a P value of <.05 was deemed statistically significant. Table 2 
| RE SULTS
| Incidence of resistant CMV
| Characteristics of patients tested for CMV resistance
| Clinical outcomes of resistant CMV
Twenty-one of 220 CMV R+ recipients (10.4%) developed CMV disease by 1 year from HCT. CMV resistance mutations were confirmed in 11 of the 21 patients with CMV disease. Of 19 patients with confirmed mutations, 11 patients had CMV disease (Table 3 ). 
TA B L E 3 (Continued)
F I G U R E 2 (A) CMV kinetics of a patient with confirmed UL97 mutation (patient #10). Description: A 64-y-old male with IgA kappa multiple myeloma, s/p autologous transplant x2, received CD34 + -selected HCT from mismatched unrelated donor, after conditioning with busulfan, melphalan, fludarabine, and rabbit antithymocyte globulin. The patient's CMV serology was positive and donor's CMV serology was negative. CMV viremia was treated with GCV induction, then maintenance. On day +152, breakthrough CMV viremia occurred on GCV maintenance. The CMV VL was 11 208 IU/mL and CMV sequencing showed the UL97 mutation (A594V). The patient received FOS and CMV CTLs. On day +221, CMV VL rose to 188 574 IU/mL. On day +224, the patient was enrolled in the MBV phase 2 study with good virologic response. On day +251, the patient was admitted to hospital due to altered mental status. CMV VL in the plasma and cerebrospinal fluid was 553 IU/mL and 16 400 IU/mL, respectively. CMV sequencing from the plasma showed the UL97 mutation (A594V). CMV from the cerebrospinal fluid was not sent for resistance testing. The UL54 target could not be amplified likely due to a polymorphism within the primer binding site of one of the PCR products. CMV, cytomegalovirus; FOS, foscarnet; GCV, valganciclovir or ganciclovir; HCT, hematopoietic stem cell transplantation; MBV, maribavir; VL, viral load. B, CMV kinetics of a patient with confirmed UL54 mutation (patient #18). (B) A 65-y-old female with myelodysplastic syndrome received CD34 + HCT from mismatched unrelated donor after conditioning with busulfan, melphalan, fludarabine, and rabbit antithymocyte globulin. The patient and donor were both CMV-seropositive. On day +21, GCV was started for CMV viremia. Later, it was switched to FOS due to cytopenia. On day +80, CMV VL started to increase on maintenance FOS. ADV VL was noted to rise as well. On day +90, BCV (CMX001) was started for ADV viremia with good response. The patient required several interruptions of BCV for management of diarrhea in the next few weeks. GCV was added to BCV with control of CMV. On day +150, CMV started to rise again. On day +164, CMV VL was 3000 IU/mL. The patient had new oxygen requirements and an abnormal chest x-ray. On day +170, CMV resistance test showed a mixed population (Wild type and N408K). On day +93, only N408K was detected. ADV, adenovirus; BCV, brincidofovir; CDV, cidofovir; CMV, cytomegalovirus; FOS, foscarnet; GCV, valganciclovir or ganciclovir; HCT Hematopoietic stem cell transplantation; VL, viral load breakthrough CMV viremia with GCV-resistant CMV after prolonged suppression with GCV. After a course of FOS and CMV CTLs, he was enrolled in the MBV trial for resistant/refractory CMV. 18 After initial virologic response, he developed fatal CMV encephalitis.
Patient #18 ( Figure 2B ) was treated with a prolonged course of FOS followed by GCV and concomitant BCV for adenovirus (ADV). 19 After resistance to GCV and CDV were identified, the patient received FOS, however eventually she expired from CMV pneumonitis. 
| Lymphocyte counts
| D ISCUSS I ON
We describe rates and outcomes of resistant CMV in a large contemporary cohort of adult, CMV R+ recipients of CD34 + -selected HCT after myeloablative or reduced intensity conditioning. The
CliniMACS system used for CD34 + selection achieves a 5 log 10 depletion of CD3 + cells 27 compared to older systems that achieved a 3-5 log 10 depletion. 20 Our patients were monitored for CMV by PCR and managed preemptively. CMV resistance testing was at the clinicians' discretion. Confirmed resistance mutations were identified in 19 (9%) patients at 1 year from HCT. Similar rates have been recently reported for haploidentical HCT. 3 CMV resistance mutations were identified >100 days from HCT in 74% (14/19) of cases and a median of 114 (IQR 72-140) days of CMV antiviral therapy.
Fifty percent of patients with CMV resistance mutations had CMV VL ≥1000 IU/mL for ≥6 weeks of preemptive therapy. In contrast, CMV resistance was identified within 2 weeks of therapy for the first episode of CMV viremia in only 2 patients. One patient had a canonical UL97mutation conferring high level GCV resistance and the other patient had a UL54 mutation conferring low level resistance to GCV and CDV. Both patients responded well to treatment with FOS and had robust ALCs, CD4 + and CD8 + counts by 6 months from HCT. GCV resistance due to CMV infection with a resistant virus was first reported in 1989. In addition, GCV resistance may arise due to infection with a susceptible virus that becomes resistant during treatment or infection first by a susceptible strain and later by a genetically distinct, resistant strain. 21 While CMV infection with a resistant strain is uncommon, resistance in the setting of prolonged exposure to GCV and persistent CMV replication was reported in 38% of patients with acquired immunodeficiency syndrome and CMV retinitis that continued to excrete CMV after 3 months of GCV. Our study has several limitations inherent to its observational nature. First, we may have underestimated the incidence of CMV resistance as only patients with clinically suspected resistance were tested. We included only probable or definite cases of CMV endorgan disease, thus we may have underestimated the incidence of CMV disease in patients who had contraindications for invasive procedures. In addition, there was substantial heterogeneity in types and dosing of antivirals and other treatment modalities used as preemptive therapy.
While acknowledging these limitations, our study provides real world data on CMV for a large, contemporary cohort of CD34 + -selected HCT using the Food and Drug Administration approved method for CD34 + selection. The currently ongoing BMT CTN trial, Progress II, is using the same method for CD34 + selection. 27 Therapeutic options are currently limited for patients with resistant or refractory CMV. MBV, a CMV-specific antiviral is active for CMV strains resistant to GCV and FOS. 28, 29 In a phase 2 study of MBV at doses 400-1200mg twice daily, 67% of patients with resistant or refractory CMV achieved undetectable VLs by week 6; however, recurrence of CMV viremia occurred in approximately 30% of responders. 30 Recurrence was most frequently seen among patients with a high VL at baseline which is a particular concern for CD34 + -selected recipients. MBV has poor penetration into the central nervous system. 26 The development of CMV encephalitis in the setting of declining VLs in our patients treated with MBV underscores the need for continued vigilance for central nervous system symptoms during treatment with MBV. MBV is also in development for preemptive therapy. 31 Given the lack of myelotoxicity, early and prolonged preemptive therapy with MBV seems feasible and could potentially minimize breakthrough resistance observed after dose interruptions and adjustments with current antivirals.
CMV prevention is an attractive approach to minimize emergence of resistance. Recipients of CD34 + -selected or haploidentical grafts may be optimal candidates for CMV prevention given the high rates of CMV viremia and the necessity for prolonged antiviral therapy to suppress CMV replication. Letermovir (LTV), a CMV DNA terminase complex inhibitor was recently approved for CMV prophylaxis in adult CMV R + HCT recipients. 32 In a phase 3 trial, LTV administered through day +100 in CMV seropositive HCT recipients was effective in preventing CMV viremia or end-organ disease through week 24 after HCT. Compared to placebo, patients on LTV had a survival advantage at 6 months after HCT. Notably only 4% of patients on the trial received CD34 + -selected HCT. [33] [34] [35] Extending CMV prevention beyond day +100 merits further study in CD34 + -selected HCT recipients specifically given the requirement for prolonged maintenance therapy. CD34 + -selected HCT recipients may also be ideally suited for adoptive cell therapy to restore CMV immunity as they do not require pharmacologic immunosuppression and have low rates of acute graft vs host disease. Well-designed, randomized clinical trials are warranted to formally compare the two modalities.
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